Asahi Kasei Acquires German Biopharmaceutical Company Aicuris
Asahi Kasei has completed its acquisition of Aicuris, a German biopharmaceutical company, for approximately €780 million. The acquisition strengthens Asahi Kasei's global pharmaceutical platform, particularly in the area of severe infectious diseases, with Aicuris bringing three antiviral assets at various stages of development. The deal is expected to contribute significantly to Asahi Kasei's future revenue through existing and upcoming products.
Topics: acquisition biotech global expansion M&A pharmaceutical